Amy Li
About Amy Li
Amy Li is the Vice President of Equity Research in Biotechnology at Jefferies, with a background in pharmaceutical sciences and extensive experience in both academia and industry.
Vice President Equity Research at Jefferies
Amy Li currently serves as the Vice President of Equity Research in Biotechnology at Jefferies. She has been with the company since 2021. Known for her in-depth analysis and forward-thinking approach, Amy's role involves providing strategic insights and detailed equity research within the biotechnology sector. Located in the New York City Metropolitan Area, she continues to contribute to the firm's strong reputation in financial services.
Senior Associate Equity Research at Wolfe Research
Before joining Jefferies, Amy Li worked at Wolfe Research, LLC as a Senior Associate in Equity Research, focusing on Biotechnology and Special Pharma. During her tenure from 2018 to 2021, she developed a reputation for thorough research and strong analytical skills in the Greater New York City Area. Her work contributed significantly to the firm's research output and client advisory services.
Adjunct Professor at Ernest Mario School of Pharmacy
Amy also gained academic experience serving as an Adjunct Professor at the Ernest Mario School of Pharmacy from 2017 to 2018. In this role, she was responsible for educating and mentoring future pharmacists, sharing her extensive knowledge gained from her professional and academic pursuits. Her contribution spanned 11 months in the Greater New York City Area.
Doctor of Pharmacy from UNC Eshelman School of Pharmacy
Amy Li achieved her Doctor of Pharmacy (Pharm.D.) from the UNC Eshelman School of Pharmacy, graduating Cum Laude. She attended from 2013 to 2017, during which she developed a solid foundation in pharmaceutical sciences. Her academic excellence set the stage for her successful career in biotechnology and equity research.
Bachelor of Science from University of North Carolina at Chapel Hill
Amy completed her Bachelor of Science in Pharmaceutical Sciences at the University of North Carolina at Chapel Hill between 2011 and 2013. This early academic achievement provided her with the necessary groundwork in pharmaceutical sciences, leading to her advanced studies and subsequent professional success in the field of biotechnology and pharmaceutical research.